The FDA accepted a New Drug Application for fezolinetant, a novel, nonhormonal selective neurokinin-3 receptor (NK3R) antagonist for the treatment of menopause-related vasomotor symptoms.
The transition to menopause, or perimenopause, represents the passage from reproductive to non-reproductive life. During the perimenopause, women experience irregular menstrual cycles, which reflect the large fluctuations in ovarian hormone [...]
Zuranolone has antidepressant effects in women with severe PPD, observed as early as 3 days after initiation of treatment. Â
In this phase II study, sepranolone 10 mg administered subcutaneously during the late luteal phase reduced PMDD symptoms more than placebo.
Intranasal oxytocin improves mood in postpartum women but has no impact on mood in women with more severe depressive symptoms.
The FDA will review zuranolone for the treatment of depression in the first half of 2022.
This review discusses the novel neurosteroid antidepressant brexanolone for the treatment of postpartum depression.
Neuroactive steroids, derivatives of allopregnanolone, may be effective for the treatment of premenstrual dysphoric disorder.
NPR’s 1A Live hosts an episode focusing on perinatal depression, including information on the new medication zuranolone for the treatment of postpartum depression.Â
Zuranolone has antidepressant effects in women with severe PPD, observed as early as 3 days after initiation of treatment. Â
